Evidence map›Paper›PMID 38352313›Full record

ArticlebioRxiv : the preprint server for biology2024

Development of non-sedating antischistosomal benzodiazepines.

Md Yeunus Mian, Dishary Sharmin, Prithu Mondal, Jawad Bin Belayet, M Mahmun Hossain, Paul McCusker, Kaetlyn T Ryan, Alexander Y Fedorov, Heather A Green, Spencer S Ericksen and 4 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Md Yeunus MianDepartment of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
Dishary SharminDepartment of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
Prithu MondalDepartment of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
Jawad Bin BelayetDepartment of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
M Mahmun HossainDepartment of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
Paul McCuskerDepartment of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, Milwaukee, WI, United States of America.
Kaetlyn T RyanDepartment of Pathobiological Sciences, University of Wisconsin - Madison, Madison, WI, USA.
Alexander Y FedorovUW Carbone Cancer Center, University of Wisconsin - Madison, Madison, WI, USA.
Heather A GreenUW Carbone Cancer Center, University of Wisconsin - Madison, Madison, WI, USA.
Spencer S EricksenUW Carbone Cancer Center, University of Wisconsin - Madison, Madison, WI, USA.
Mostafa ZamanianDepartment of Pathobiological Sciences, University of Wisconsin - Madison, Madison, WI, USA.ORCID 0000-0001-9233-1760
V V N Phani Babu TiruveedhulaDepartment of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
James M CookDepartment of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
John D ChanDepartment of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, Milwaukee, WI, United States of America.ORCID 0000-0003-4986-972X
University of Wisconsin–Milwaukee · USUniversity of Wisconsin–Madison · USMedical College of Wisconsin · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
ANXIOLYTIC EFFECTS AND ABUSE OF BZ RECEPTOR LIGANDSR01DA011792 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI ROWLETT, JAMES K · 1998 to 2024
$7.8M
Tolerance and Physical Dependence after Chronic Benzodiazepine TreatmentR01DA043204 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI JAMES K ROWLETT · 2017 to 2026
$4.3M
Synthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic PainR01NS076517 · NINDS · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2012 to 2015
$1.3M
Development of non-sedative, parasite-selective benzodiazepines to treat the neglected tropical disease schistosomiasisR21AI146540 · NIAID · UNIVERSITY OF WISCONSIN OSHKOSH · PI CHAN, JOHN D · 2020 to 2021
$405k
NCI NIH HHS P30 CA014520NIAID NIH HHS HHSN272201700014CNIAID NIH HHS R21 AI146540NIDA NIH HHS R01 DA011792NIDA NIH HHS R01 DA043204NINDS NIH HHS R01 NS076517
6 · The paper itself

Abstract

The neglected tropical disease schistosomiasis infects over 200 million people worldwide and is treated with just one broad spectrum antiparasitic drug (praziquantel). Alternative drugs are needed in the event of emerging praziquantel resistance or treatment failure. One promising lead that has shown efficacy in animal models and a human clinical trial is the benzodiazepine meclonazepam, discovered by Roche in the 1970's. Meclonazepam was not brought to market because of dose-limiting sedative side effects. However, the human target of meclonazepam that causes sedation (GABA

Identifiers

PMID38352313
PMCPMC10862742
OpenAlexW4391305673

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.